The Angi Ads business connects consumers with service professionals for local services through the Angi nationwide online directory of service professionals in various service categories. It provides consumers with valuable tools, services and content, including verified reviews, to help them research, shop and hire for local services, and it sells term-based website and mobile and digital magazine advertising to service professionals, as well as provides quoting, invoicing and payment services.

The company also owns and operates Angi Leads digital marketplace service, which connects consumers with service professionals for home repair, maintenance and improvement projects; offers consumers with tools and resources to find local, pre-screened and customer-rated service professionals, as well as online appointment booking; and connects consumers with service professionals by telephone and home services-related resources.

Angi also operates Handy, a platform for household services, primarily cleaning and repair services; Angi Roofing, which provides roof replacement and repair services; and home services marketplaces under the Travaux, MyHammer, Werkspot, MyBuilder and Instapro names.

Goldman Sachs has a $9 price target for Angi stock. The consensus target is higher at $9.68, and shares closed at $5.45 on Friday. Hitting the Goldman Sachs target would be about a 60% gain.

GoodRx

This company has used relentless television advertising to gain market share. GoodRx Holdings Inc. (NASDAQ: GDRX) offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States.

The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.

GoodRx also offers other health care products and services, including subscriptions, pharma manufacturer solutions and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies.

The Goldman Sachs price target is $12, and the consensus target for GoodRx stock is $12.24. Friday’s final trade was for $7.58 a share. Hitting the Goldman Sachs target would be a 50% or so gain.